High placenta-specific 1/low prostate-specific antigen expression pattern in high-grade prostate adenocarcinoma

Abstract

Our findings on differential expression of PLAC1 in PCa plus its positive association with Gleason score and negative correlation with PSA expression highlight the potential usefulness of PLAC1 for targeted PC therapy especially for patients with advanced disease.

Placenta-specific protein 1 (PLAC1) is a unique onco-fetal-placental protein and an underappreciated therapeutic target in cancer

“…Nonetheless, a consensus among those who have investigated PLAC1 in cancer is that anti-PLAC1 immunotherapy is a useful avenue to pursue, particularly in cancers of the breast, uterus and ovary where the prevalence of PLAC1 induction appears to be the highest. The same conclusion was reached for prostate cancer [33].…”

“…In all of these studies there were hints that PLAC1 expression positively correlates with clinical features, including stage and grade and survival. A clear relationship between relative PLAC1 mRNA level and stage was reported in uterine cancers [3] and between PLAC1 protein, as measured by immunohistochemistry, and Gleason Score in prostate cancer [33]. Further, in the latter study there was a marked progression of PLAC1 expression from little to none in non-neoplastic/nonhyperplastic prostate tissue through steady increases in benign prostate hyperplasia (BPH), through the potential cancer precursor state highgrade prostate intraepithelial neoplasia (HPIN) and, ultimately, to frank prostate carcinomas.…”

“…In addition, this group added evidence of PLAC1 expression in a further 66 cancer cell lines extending the scope of PLAC1 expression an additional ten cancer types. These papers were followed by evidence of PLAC1 expression in hepato-cellular carcinoma [29], colorectal cancer [30], ovarian cancer [31], gastric cancers [32], uterine cancer [3] and prostate cancer [33]. In all of these studies there were hints that PLAC1 expression positively correlates with clinical features, including stage and grade and survival.…”

New tumour antigen PLAC1/CP1, a potentially useful prognostic marker and immunotherapy target for gastric adenocarcinoma

“…We have discussed these details in a previously published article 5. Ghods et al 10 found that differential expression of PLAC1 in prostate cancer, its positive association with the Gleason score, and its negative correlation with prostate specific antigen (PSA) expression highlighted the potential usefulness of PLAC1 for developing targeted prostate cancer therapies, particularly for patients with advanced disease. Wang et al 11 found that PLAC1 expression was observed in tumour cell lines derived from breast, ovary and prostate.…”

Expression of Cancer Testis Antigens in Colorectal Cancer: New Prognostic and Therapeutic Implications

“…In our hands, MAGEA3 and PLAC1 were not only overexpressed in CRC, but what is even more important, their expression increased together with disease progression, according to the Dukes classification. Thus, MAGEA3 and PLAC1 may have some prognostic value, as observed in nonsmall lung cancer [28], renal carcinoma [29], or prostate adenocarcinoma [30]. …”